Aim: Coagulation disorders may develop in association with severe acute pancreatitis (AP). Plasma thrombin-antithrombin III complex (TAT) levels are one of the principal markers of coagulation disorder. The purpose of this study was to evaluate TAT and other hemostatic parameters in patients with AP and to examine whether or not these parameters indicate the severity of AP.
Method: Forty-six patients with AP (14 severe, 32 non-severe) and a 30-member healthy control group were recruited. The severity of AP was determined using the revised Atlanta classification. ELISA was used to measure patients' plasma TAT levels.
Results: The TAT levels of AP patients at presentation were higher than those of the control group (p = 0.005). The plasma TAT levels of patients with severe AP were also significantly higher than those of patients with non-severe AP (p = 0.05) and of the control group (p < 0.001). The general accuracy, sensitivity and specificity of TAT levels in predicting the severity of AP were 77.4, 77.8, and 77.3% respectively.
Conclusion: The coagulation cascade was activated in the AP patients in our study, and this was shown to become more pronounced as severity of the disease increased. Plasma TAT levels at the time of presentation in patients with AP can be used as a marker for predicting the severity of the disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000485613 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Time-resolved single-cell secretion analysis microfluidics.
Lab Chip
January 2025
Department of Biomedical Engineering, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon Tong, Hong Kong, China.
Revealing how individual cells alter their secretions over time is crucial for understanding their responses to environmental changes. Key questions include: When do cells modify their functions and states? What transitions occur? Insights into the kinetic secretion trajectories of various cell types are essential for unraveling complex biological systems. This review highlights seven microfluidic technologies for time-resolved single-cell secretion analysis: 1.
View Article and Find Full Text PDFAttoampere Level Leakage Current in Chemical Vapor Deposition-Grown Monolayer MoS Dynamic Random-Access Memory in Trap-Assisted Tunneling Limit.
ACS Nano
January 2025
BK21 Graduate Program in Intelligent Semiconductor Technology, Seoul 03722, Republic of Korea.
MoS, one of the most researched two-dimensional semiconductor materials, has great potential as the channel material in dynamic random-access memory (DRAM) due to the low leakage current inherited from the atomically thin thickness, high band gap, and heavy effective mass. In this work, we fabricate one-transistor-one-capacitor (1T1C) DRAM using chemical vapor deposition (CVD)-grown monolayer (ML) MoS in large area and confirm the ultralow leakage current of approximately 10 A/μm, significantly lower than the previous report (10 A/μm) in two-transistor-zero-capacitor (2T0C) DRAM based on a few-layer MoS flake. Through rigorous analysis of leakage current considering thermionic emission, tunneling at the source/drain, Shockley-Read-Hall recombination, and trap-assisted tunneling (TAT) current, the TAT current is identified as the primary source of leakage current.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China.
Background: Alzheimer's disease (AD) is a devastating neurodegenerative disease with delayed diagnosis until the manifestation of symptoms. Although the emergence of blood-based biomarkers offers hope for easy detection of AD, existing AD-associated blood biomarkers, known as the "blood ATN biomarkers", mainly capture the pathological hallmarks of AD, overlooking other AD-associated biological processes such as inflammation and vascular dysfunctions. Therefore, developing a blood-based biomarker assay that captures dysregulation beyond the ATN biomarkers may help advance early detection and staging of AD, enabling a comprehensive examination of the disease status METHOD: We leveraged ultrasensitive proteomic technology to develop a blood-based, multiplex biomarker assay for AD.
View Article and Find Full Text PDFBackground: The relationship between sleep and AD is unclear: sleep problems may contribute to AD pathogenesis, but the spreading of AD pathology across the brain may also de-regulate sleep. What aspect of sleep is relevant in which disease phase is also unclear, as many studies are based on questionnaires. We study sleep efficiency and rapid eye movement (REM) sleep, objectively measured using an activity tracker to shed light on sleep disturbances across the AD spectrum.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands.
Background: Individuals with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) show variability in cognitive decline. Little is known about the underlying mechanisms, but these are likely to depend on tau levels. Using untargeted proteomics in cerebrospinal fluid (CSF), we studied which processes were associated with cognitive decline in A+T- and A+T+ MCI individuals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!